AllDocs -> cancers

GEArray Q Series Human Androgen Signaling and Prostate Cancer Gene Array Cat. No. (Rad / Non-Rad) * Kit HS-031- 02 / HS-031N-02 2 Arrays HS-031- 04 / HS-031N-04 4 Arrays HS-031-12 / HS-031N-12 12 Arrays Description GEArray Q Series Androgen Signaling and Prostate Cancer Gene Array is designed to assess the role of 96 genes in androgen-regulated processes that are involved in malignant transformation of prostate gland. Androgen signaling plays an important role in the pathogenesis of prostate cancer , as exemplified by androgen ablation therapy for advanced prostate cancer . Activation of the PI3K/AKT/FRAP pathway has also been found to contribute to hormone resistant growth of recurrent prostate cancer . On the Androgen Signaling and Prostate Cancer Gene Array, ...

Pediatric Neuro-Oncology Clinical Trials National Cancer Institute in Bethesda, Maryland CONTACT INFORMATION: Call the Neuro-Oncology Patient Referral Line at 301-402-6298 Study Title and Basic Eligibility Treatment Plan Any primary CNS tumor NCI-01-C-0070 Evaluation of the natural history of patients with CNS tumors • Patients must have any CNS tumor • Non-pharmacologic treatment protocol • Patients will be followed by consult • Diagnostic testing may be performed • Patients will have opportunity to be screened for treatment protocol Low grade gliomas, MBL/PNET, Ependymoma NCI-98-C-0074 Phase II study of intravenous Cereport® (RMP-7) and carboplatin in childhood brain tumors • Patient must have brain tumor with evidence of progression • ECOG performance of 0-2 • No more than one prior ...

Vietnamese April 2002 [BHC-6055] 1 / 1 DEPARTMENT Chˆng ung thi tuy’n ti÷n liŸt vø phiÍng phæp ch?a trfi Prostate cancer : what are the treatment options? Nam giÎi cfl mÈt tuy’n nh· s¿n xu`t ra tinh dfich g„i lø mÈt tuy’n ti÷n liŸt. Tuy’n nøy n˜m Ì {æy bøng quang (b„ng {æi) vø bao quanh Âng ti’t niŸu (lø mÈt Âng nh· dÕn niÎc ti?u t˜ bøng quang ra diÍng vŒt). T¬i Æc, Ì mÈt thÏi {i?m nøo {fl trong {Ïi mÈt ngiÏi {øn ‰ng, cˆ trong 10 ngiÏi l¬i cfl mÈt ngiÏi mƒc ph¿i chˆng ung thi tuy’n ti÷n liŸt. Chˆng nøy thiÏng x¿y ra Ì nh?ng ngiÏi tr‘n 50 tuÁi vø thiÏng gia tvng trong nh?ng thŒp ni‘n k’ {fl. Tuy nhi‘n, chˆng ung thi tuy’n ti÷n liŸt cfl khuynh hiÎng phæt tri?n chŒm vø nh?ng ngiÏi bfi ung thi kh‰ng ch’t v¤ bŸnh nøy. Ung thi tuy’n ti÷n liŸt lø g¤? ThiÏng Ì vøo tuÁi trung ni‘n (t˜ 40 trÌ l‘n), tuy’n ti÷n liŸt nÌ lÎn hÍn. V`n {÷ nøy cfl th? gy ra mÈt sÂ triŸu chˆng, ch?ng ...

Vol. 7, No. 17 June 8, 2001 ©Lisa Br ook/Lisa Brook Phototgraphy Celebrating the lives of those who fight cancer Above, Christy Russell, assistant professor of medicine and associate director of the Lee Breast Center at the USC/Norris, hugs a cancer survivor at the Festival of Life held at the HSC Quad on Saturday June 2, 2001. Right, Betsy Mushik speaks with volunteer Alice Wu at an information booth. Men who underwent radiation therapy to fight their prostate cancer report that sexual dysfunction is their most prevalent and longest-lasting quality-of-life issue after treatment, according to a Keck School researcher and colleagues. The findings, published in the May issue of the Journal of Clinical On- cology , are among the latest research coming from the vast Prostate Cancer Outcomes Study, or PCOS. ...

prostate cancer Hormel Researcher to Study Caloric Restriction and Prostate Cancer MINNEAPOLIS / ST. PAUL?Margot Cleary, an associate professor at the University of Minnesota?s Hormel Institute in Austin, Minn., has received a three-year, $375,000 grant from the U.S. Department of Defense Prostate Cancer Research Program to study how reduced caloric intake may prevent the development of prostate cancer , the most common cancer among men in the United States. The study will use male mice that develop prostate tumors in a manner similar to humans as a model system for determining the effects of chronic and intermittent caloric reductions on tumor growth. The study builds on earlier work by Cleary and her colleagues, in which she found?also working with mice?that intermittent caloric restriction followed by refeeding had a protective effect on mammary/breast tumor development. In that study, ...

Vol. 6, No. 32 November 3, 2000 Lori Oliwenstein NO TRICKS, BUT LOTS OF TREATS—Thanks to the involvement of staff and patients campus-wide, Halloween was a day of smiles and sweets for the children from the USC HSC Child Care Center, who started their trick-or- treating a little early. Keck School researchers’ investiga- tion into the roots of prostate cancer got a big boost recently, earning a $2.2 million Prostate Cancer Center Initia- tion Award from the Department of Defense. As part of the grant, Gerhard Coetzee, associate professor of urology, Richard Cote, professor of pathology and urol- ogy, and Juergen Reichardt, associate professor of biochemistry and molecu- lar biology, are investigating the pro- gression of prostate cancer . Ronald K. Ross, professor and chair of preventive medicine, coordinates ...

Notes from the Chair Last year, more ASCO members than ever sup- ported The ASCO Foundation! At this critical time in our history, when the whole- hearted dedication of all members of our community is so essential to continue the momentum against cancer , this is very good news. ASCO members support ASCO’s mission in many ways. By attending the Foundation Benefit Concert we not only enjoy a festive artistic and entertainment event, we also demonstrate our unity and sense of collective purpose. This was especially apparent last year, when Sir Elton John sang with such passion and energy to convey to us his appreciation for our leadership in the fight against cancer . We take time to read and respond to Foundation mailings. We offer personal financial support. We encourage others to support the ...

Access, Awareness, Outreach, and Advocacy: Mobile Prostate Cancer Screening as a Model for Reaching and Organizing Men Quentin Lockwood III, M.A., Jamie Bearse and Richard N. Atkins, M.D. In the United States, prostate cancer is the most commonly diagnosed non-skin cancer . 1 According to the American Cancer Society, approximately 180,000 men will be diagnosed with the disease and 32,000 men will lose their lives this year. 2 These numbers are comparable with those of breast cancer incidence and mortality in the United States. 3 Only about 7 percent of U.S. government cancer research dollars are spent on finding a cure for a disease that accounts for nearly 16 percent of all cancer cases. 4 Given these facts, the National Prostate Cancer Coalition (NPCC) developed a mobile prostate cancer ...

Prostate Cancer Awareness Week 2004 Nurses from Colchester General Hospital will next week (w/c 22nd March) be out and about in the community to promote Prostate Cancer Awareness Week. Urology cancer nurse specialist Lucy Powell and urology research sister Barbara Randall will be supported by volunteers from the North East Essex Prostate Cancer Support Group. They will take part in four prostate information sessions during the week, which is a national event spearheaded by The Prostate Cancer Charity and runs from Monday 22nd March to Sunday 28th March: Tuesday 23rd March 10am-2pm Foyer, Tesco, Highwoods Wednesday 24th March 10am-12noon Main Entrance, Colchester General Hospital Wednesday 24th March 1pm-2.30pm Colchester Cornerstone, Sir Isaac¹s Walk Thursday 25th March 10am-2pm Pharmacy, Sainsburys, Tollgate West, ...

Sponsored by E DUCATION & S UPPORT P ROGRAM and C ANCER Palouse P ROSTATE PROGRAM GOALS 1. Assist men with difficult treatment decisions. 2. Provide an educational resource on prostate cancer . 3. Assist men coping with prostate cancer 4. Providing a support group for partners of men with prostate cancer . 5. Participating in community education programs to help prevent prostate cancer and achieve early diagnosis. MEETING TIMES The Prostate Cancer Support Group meets the first Tuesday of each month from 7:30 to 9:30 pm. FOR MORE INFORMATION Please call: Bruce Palmer at 509-332-5683 Email: brucepal@gte.net ...

PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATIONP ATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATION PATIENT INFORMATIONP ATIENT INFORMATION PATIENT PATIENT INFORMATION Prostate cancer A collectable guide for you to use with your patients What is prostate cancer ? The prostate is a gland about the size of a chestnut. It lies at the base of the bladder, wrapped around the urethra – the tube that carries urine from the bladder out of the body (see above). The healthy prostate produces fluid that is added to semen to improve the motility of the sperm. ...

Hormonal Therapy in Prostate Cancer , - Overview and Recent Trend in Japan -. Hirofumi Koga and Seiji Naito Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Background, Hormonal therapy has been one of the standard treatment modalities in prostate cancer , although it has been regarded as a palliative treatment. Today, it is still selected as the initial treatment for advanced metastatic prostate cancer . Purpose, Hormonal therapy including modality and mechanism in prostate cancer is reviewed and recent trend of hormonal therapy in Japan is introduced. Results, There are many drugs in hormonal therapy at the point of action mechanism. Luteinizing hormone-releasing hormone (LHRH) agonist, medical castration, inhibits LH activity at pituitary gland. Surgical castration inhibits testosterone at testis. Non-steroidal ...

Owen Sound Prostate Cancer Support Group Notice Of Meeting A support group that provides understanding, hope, and information to prostate cancer patients and their families. Date: Place Time: Programme: July 21st 04 St Andrews Presbyterian Church 7pm Social / 7.30 meeting Round Table Page 2 Member of USTOO and CPCP and supported by the Canadian Cancer Society Chairman: Colin Campbell 519-371-4779 V/Chair & Secy: F Butler 519 372 1619 Dear Friends; I hope you are having a pleasant time this summer although it has been cool so far! Our immediate goal is to consider what we as a group can do to increase awareness in the general public of the threat which Prostate Cancer poses.The Federal Government has withdrawn special funding for Pca research while ...

June 2004 Newsletter # 43 (v. 5, 6) PCNG PROSTATE CANCER NETWORKING GROUP of Greater Cincinnati PCNG (http://www.pcngcincinnati.org) is a chapter of USToo Founder: Bob Kanter - Conveners Emeriti: Adrian Boie, Lou Stadler - Facilitators: 8/03: Stan Moczydlowski; 9/03: Steven Plymire; 10/03: Tom Young; 11/03: Steve Steiner; 1/04: Jerry Glenn; 2/04: Jack Ramsay; 5/04: Dick Fencl Newsletter (328 copies this issue) - Editors: Kees DeJong & Fran Stanton 779-0144 Adrian Boie: 1989, PSA 13, GS 9; RP, EBRT, IHT, HT 751-6888 Kees DeJong: 1996, PSA 24, GS 9; IHT, EBRT+Brachy, IHT 253-6768 John Hoffmann: 1997, PSA 5, GS 6; RP, EBRT TELEPHONE CONTACTS: 528-2769 Gordon Huntley: 1999, PSA 4, GS 9; RP and Orchiectomy 733-5745 Bill Riggs: 1995, PSA 33, GS 6; RP, EBRT, HT 761-9645 Lou ...

Brochure More information from http://www.researchandmarkets.com/reports/837 Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond Description: The prostate cancer R&D pipeline is showing a swing toward innovative therapies and away from the current standard of hormonal treatments where there is limited scope for increases in efficacy. If these new therapies are able to penetrate the market, it could soon be one of the most active areas of cancer therapy research. Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond provides an in-depth analysis of the prostate cancer pipeline, and a competitive analysis of the most promising classes and drugs in development. The report enables you to competitively position your products, strengthen your marketing strategy and market penetration, expose potential threats to your business and target R&D ...

Hein Van Poppel is Chairman of the Department of Urology at the University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium, where he has been responsible for the development of urological oncology since 1985. He is a board member of the European Society of Oncologic Urology (ESOU), of the European Society of Surgical Oncology (ESSO) and of the European Organization for Research and Treatment of Cancer (EORTC), and a member of the Executive Committee of the Residency Review Committee of the European Board of Urology (EBU). Professor Van Poppel is co- ordinator of the Belgian Uro- Oncological Study Group (BUOS) and is Treasurer of the Genito-Urinary Group of the EORTC where he is also study co-ordinator of several prostate and kidney cancer trials. He recently became Chairman of the Educational Office of the EAU (European School ...

VOL. 6 NO. 2 2004 REVIEWS IN UROLOGY 95 Prostate Cancer Quality of Life Questionnaire. Subjectively, both groups experienced a significant improvement in urgency, and the estradiol group experienced a significant improvement in urge incontinence; however, there were no significant differences between the groups. Objectively, no significant differences were demonstrated between the groups. Nine women in the estradiol group experienced vaginal bleeding, of whom 5 required a hys- terectomy during or after the study. Despite the use of numerous outcome measures, the 25-mg estradiol implant did not produce a greater improvement in urgency symptoms compared with placebo. In addition, the estradiol implant was associated with a high complication rate. These results make it is difficult justify the use of estrogen for overactive bladder symptoms. Although estro- gen may play a role ...

‘I’ll continue the fight’ ON THE CAMPAIGN TRAIL P 15.00 A COPY Founded 1898 V OLUME 105 N UMBER 197 28 PAGES 3 SECTIONS THURSDAY, APRIL 29, 2004 www. manilatimes.net e-mail: newsboy1@manilatimes.net Tel. Nos. 524-56-64 to 67 371 Bonifacio Drive, Port Area, Manila Available daily in the afternoon, sold for P6 a copy Prostate cancer easy to cure GMA: Probe shooting at Rizal checkpoint E L E C T I O N S P E A K Culiat raid exposes Abu’s drug operation FPJ, Ping join forces, but only to stop fraud It’s raining black propaganda Raul Roco, flanked by his son Rex and running mate Hermie Aquino, leads a motorcade along Ayala Avenue shortly after arriving home Wednesday ...

March 2004 Newsletter # 40 (v. 5, 3) PCNG PROSTATE CANCER NETWORKING GROUP of Greater Cincinnati PCNG (www.pcngcincinnati.org) is a chapter of USToo Founder: Bob Kanter - Conveners Emeriti: Adrian Boie, Lou Stadler - Facilitators: 8/03: Stan Moczydlowski; 9/03: Steven Plymire; 10/03: Tom Young; 11/03: Steve Steiner; 1/04: Jerry Glenn; 2/04: Jack Ramsay Newsletter (325 copies this issue) editors: Kees DeJong & Fran Stanton 779-0144 Adrian Boie: 1989, PSA 13, GS 9; RP, EBRT, IHT 751-6888 Kees DeJong: 1996, PSA 24, GS 9; IHT, EBRT+Brachy, IHT 253-6768 John Hoffmann: 1997, PSA 5, GS 6; RP, EBRT TELEPHONE CONTACTS: 528-2769 Gordon Huntley: 1999, PSA 4, GS 9; RP and Orchiectomy 733-5745 Bill Riggs: 1995, PSA 33, GS 6; RP, EBRT, HT 761-9645 Lou Stadler: 1987, PSA ...

prostate cancer Prostate Cancer in Maryland Preliminary Report of the Prostate Cancer Committee Prostate Cancer Committee Members Donna Cox, co-chair, Johns Hopkins Katherine Farrell, MD, co-chair, Anne Arundel County Health Department Members THANK YOU! Prostate Cancer - Incidence Most common cancer among men (excluding skin cancer ). 3,869 new prostate cancer cases diagnosed in MD in 1999. MD’s incidence rate is significantly higher than U.S. incidence rate. Prostate Cancer - Incidence Prostate Cancer - Incidence Prostate Cancer - Mortality ...

February 2004 Newsletter #39 (v. 5, 2) PCNG PROSTATE CANCER NETWORKING GROUP of Greater Cincinnati PCNG (ww.pcngcincinnati.org) is a chapter of USToo Founder: Bob Kanter - Conveners Emeriti: Adrian Boie, Lou Stadler - Facilitators: 8/03/: Stan Moczydlowski; 9/03: Steven Plymire; 10/03: Tom Young; 11/03: Steve Steiner; 1/04: Jerry Glenn Newsletter (324 copies this issue) editors: Kees DeJong & Fran Stanton 779-0144 Adrian Boie: 1989, PSA 13, GS 9; RP, EBRT, IHT 751-6888 Kees DeJong: 1996, PSA 24, GS 9; IHT, EBRT+Brachy, IHT 253-6768 John Hoffmann: 1997, PSA 5, GS 6; RP, EBRT TELEPHONE CONTACTS: 528-2769 Gordon Huntley: 1999, PSA 4, GS 9; RP and Orchiectomy 733-5745 Bill Riggs: 1995, PSA 33, GS 6; RP, EBRT, HT 761-9645 Lou Stadler: 1987, PSA NA, GS 7; EBRT, ...

Professor Dimos Baltas is Director of the Department for Medical Physics and Engineering, Department for Radiation Oncology at Klinikum Offenbach in Germany. Dr Thomas Martin is Assistant Director of the Department for Radiation Oncology and Consultant for Prostate Brachytherapy at Klinikum Offenbach. Professor Ulf W Tunn is Director of the Department for Urology at Klinikum Offenbach. Professor Nikolaos Zamboglou is Director of the Department for Radiation Oncology at Klinikum Offenbach. a report by P r o f e s s o r D i m o s B a l t a s 1 , D r T h o m a s M a r t i n 1 , P r o f e s s o r U l f W T u n n 2 and P r o f e s s o r N i k o l a o s Z a m b o g l o u 1 1. Department for Radiation Oncology, Klinikum Offenbach, and 2. Department for ...

Professor Claude Schulman is Chief of the Department of Urology, Erasme Hospital, University Clinics of Brussels, and Professor of Urology at the University of Brussels. He is currently Editor-in- Chief of European Urology , the official journal of the European Association of Urology (EAU), and serves on the editorial boards of Urology , Current Opinion in Urology , the Journal of Endourology and others. Since receiving his MD and PhD degrees, he has published more than 500 papers, mostly in international urological journals, and has contributed numerous chapters to several internationally renowned textbooks in urology. Professor Schulman is also the author of five books on urology. He is a member of 20 international scientific societies and has been an active participant in over 500 international meetings and an invited Guest Professor at numerous ...

January 2004 Newsletter #38 (v. 5, 1) PCNG PROSTATE CANCER NETWORKING GROUP of Greater Cincinnati PCNG ( http://www.pcngcincinnati.org ) is a chapter of USToo Founder: Bob Kanter - Conveners Emeriti: Adrian Boie, Lou Stadler - Facilitators: 8/03/: Stan Moczydlowski; 9/03: Steven Plymire; 10/03: Tom Young; 11/03: Steve Steiner; 1/04: Jerry Glenn Newsletter (324 copies this issue) editors: Kees DeJong & Fran Stanton 779-0144 Adrian Boie: 1989, PSA 13, GS 9; RP, EBRT, IHT 751-6888 Kees DeJong: 1996, PSA 24, GS 9; IHT, EBRT+Brachy, IHT 253-6768 John Hoffmann: 1997, PSA 5, GS 6; RP, EBRT TELEPHONE CONTACTS: 528-2769 Gordon Huntley: 1999, PSA 4, GS 9; RP and Orchiectomy 733-5745 Bill Riggs: 1995, PSA 33, GS 6; RP, EBRT, HT 761-9645 Lou Stadler: 1987, PSA NA, GS ...

Feasibility Study for the Treatment of Brachytherapy Failure Prostate Cancer using High-Intensity Focused Ultrasound Ralf Seip 1 , David Shaeffer 2 , Peter Lawrence 2 , Thomas A. Gardner 2 , Michael O. Koch 2 , Liang Cheng 2 , Adam Wunderlich 1 , Cory Miller 1 and Narendra T. Sanghvi 1 1 Focus Surgery, Inc., Indianapolis, IN., 46226, USA. 2 Indiana University School of Medicine, Indianapolis, IN., USA. Abstract. Prostate cancer patients who were previously treated using Brachytherapy and have recurrence of cancer are currently being excluded from ongoing prostate cancer clinical trials utilizing HIFU. It is thought that the presence of seeds in the prostate may obstruct HIFU energy delivery. ...

Prostate Cancer 2003 RK Illango, MD Risk Management Consultant Page 2 Scope Current problems in Underwriting Evaluating abnormal PSA Prostate nodule, when is it significant? When & how to rate an appropriately treated cancer ? When is an untreated cancer insurable? What does elevated PSA post-treatment mean? Page 3 Elevated PSA Page 4 Elevated PSA PSA lab normal values Be aware of values from different labs. PSA 3 to 10 have 25% probability of cancer PSA velocity Determined over 3 to 6 years Annual increase of more than 20% or >0.8ng/ml PSA can fluctuate by as much as20 to 30% in a normal person Page 5 Elevated PSA PSA density(PSAD) PSA/ prostate ...

prostate cancer Management of Locally Invasive Prostate Cancer Made possible under an educational grant from: Case 2 Learning objectives Discussion of this case will assist urologists to: Examine the rationale behind lymph node dissection in the staging of prostate cancer Define the role of hormone therapy as neoadjuvant or adjuvant treatment along with radiotherapy Discuss the rationale for early versus late hormone therapy Case Presentation Ron Mintz 59 y.o. businessman Previous vasectomy, appendectomy Nonsmoker, no medications No other major medical problems History Increasing LUTS for two years Primarily obstructive symptoms, no hematuria Has delayed seeing urologist for months - “busy” Examination General examination ...